The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
Explore this paper's citation graph
Summary
It is demonstrated that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels and was also greater in patients with higher pretreatment levels of LDL cholesterol.
- Type
- article
- Published
- 1996-10-03
- Cited by
- 6,558
- References
- 27
- Access
- Open access
- OpenAlex
- https://openalex.org/W2322095705
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24176210
Keywords
Pravastatin, Medicine, Myocardial infarction, Placebo, Internal medicine
References
- Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
- Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
- Cholesterol reduction and its impact on coronary artery disease and total mortality.
- Lipid-lowering interventions in angiographic trials.
- Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.
- Decreased HDL2 and HDL3 Cholesterol, Apo A‐I and Apo A‐II, and Increased Risk of Myocardial Infarction
- Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease.
- Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.
- National Cholesterol Education Program's recommendations, and implications of "missing" high-density lipoprotein cholesterol in cardiac rehabilitation programs.
- Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.
- Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)
- Range of serum cholesterol values in the population developing coronary artery disease.
- Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group.
- Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
- Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys.
- Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
- The Statistical Analysis of Failure Time Data
- Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators.
- Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)
- Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Cited by
- Prävention des linksventrikulären Remodelings
- Imaging of coronary artery calcification. Its importance in assessing atherosclerotic disease.
- Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)
- Pharmacological treatment of diabetic patients with cardiovascular complications
- Association between coronary angiograms and cardiac events--a prospective 3-year follow-up. INTACT-Investigators. International Nifedipine Trial on Antiatherosclerotic Therapy.
- Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment.
- Systemic Immune Reactions to HMG‐CoA Reductase Inhibitors: Report of 4 Cases and Review of the Literature
- Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis.
- Low density lipoprotein (LDL)-mediated suppression of Lewis lung carcinoma in hypercholesterolemic LDL receptor-deficient mice.
- Joint British recommendations on prevention of coronary heart disease in clinical practice
- Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
- Non‐lipid properties of statins
- Secondary prevention in coronary heart disease
- Pathophysiology and clinical significance of atherosclerotic plaque rupture.
- Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
- Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
- Cholesterol lowering and endothelial function.
- Beyond lipids - the role of the endothelium in coronary artery disease.
- Is cholesterol a risk factor for stroke?: No.
- Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease.
Related papers
- Comparison of Fluvastatin and Pravastatin in Therapeutic Effect for Hyperlipidemia
- [Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study].
- Pravastatin for lowering lipids.
- A Review of Analytical Methods for Determination of Pravastatin in Pharmaceutical Dosage Forms and Biological Fluids
- Fluvastatin vs pravastatin in treating hyperlipidemia
- Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events.
- The Effect of Early Intensive Pravastatin Theapy on Baroreflex and Chemoreflex Sensitivity After Acute Myocardial Infarction.
- Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
- Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.
- High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs.